References
- Thun M J, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, phar-macologic and clinical issues. J Natl Cancer Inst 2002; 94: 252–266.
- Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nature Rev Cancer 2001; 1: 11–21.
- Steinbach G, Lynch PM, Phillips RK et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenoma-tous polyposis. N Engl J Med 2000; 342: 1946-1952.
- Manson MM. Cancer prevention - the potential for diet to modulate molecular signalling. Trends Molec Med 2003; 9: 11–18.
- Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenoma-tous polyposis. Cancer Res 1996; 56: 2556-2560.
- Ritland SR, Gendler SJ. Chemoprevention of intestinal adenomas in the Apc(Min) mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression. Carcinogenesis 1999; 20: 51–58.
- Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preven-tive and therapeutic agent in the Min mouse model of adeno-matous polyposis. Cancer Res 2000; 60: 5040-5044.
- Huls G, Koornstra JJ, Kleibeuker JH. Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. Lancet 2003; 362: 230–232.
- Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adeno-matous polyposis. N Engl J Med 1993; 328: 1313–1316.
- Sharma RA, McLelland HR, Ireson CR, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001; 7: 1894–1900.
- Garcea G, Jones DJL, Dennison AR, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 2004; 90: 1011–1015.